A Phase 2 interventional study of APR-246 and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) in High-grade Serous Ovarian Cancer, sponsored by Aprea Therapeutics. Completed at 12 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-17.
Sponsored by Aprea Therapeutics · Phase 2, Interventional, and Treatment
The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and PLD chemotherapy regimen in patients with platinum-resistant recurrent high grade serous ovarian cancer (HGSOC) with mutated TP53. In addition, the study aims to assess the safety profile of the combined APR-246 and PLD chemotherapy regimen, to evaluate potential biomarkers, and to assess the biological activity in tumor and surrogate tissues. The trial will enroll at least 25 evaluable patients.
3,381 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
This study's enrollment of 36 is below the median of 54 across 2,548 interventional studies indexed under Ovarian Neoplasms.
Browse Ovarian Neoplasms studies →Aprea Therapeutics is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: APR-246 · Drug: Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Intravenous infusion
Intravenous infusion
Overall Response Rate (ORR)
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Up to 18 months
Treatment-emergent Adverse Events With Combined APR-246 and PLD Regimen
Treatment emergent adverse events (TEAEs) were defined as AEs that occurred on or after the first dose of study medication up to and including 30 days after last dose. AEs were graded according to NCI CTCAE (Version 4.0). Patients with multiple TEAEs were only counted once within a summary category: SOC, PT, maximum grade, or relationship to treatment. Patients with events in more than one category were counted once within each category.
Time frame: Treatment emergent adverse events (TEAEs) were defined as AEs that occurred on or after the first dose of study medication up to and including 30 days after last dose. Median number of 28d Cycles=2.5 (Min = 1, Max = 14)
| Milestone | APR-246 (4.5g/6hr) + PLD | APR-246 (4.5g/3hr) +PLD | APR-246 (4.5g/4hr) +PLD | APR-246 (3.7g/4hr) +PLD |
|---|---|---|---|---|
| Started | 28 | 3 | 2 | 3 |
| Completed | 28 | 3 | 2 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| Participants | APR-246 (4.5g/6hr) + PLD | APR-246 (4.5g/3hr) + PLD | APR-246 (4.5g/4hr) + PLD | APR-246 (3.7g/4hr) + PLD |
|---|---|---|---|---|
| Partial Response (PR) | 1 | 0 | 0 | 0 |
| Stable Disease (SD) | 15 | 2 | 1 | 1 |
| Progressive Disease (PD) | 7 | 0 | 1 | 2 |
| Not Evaluable | 0 | 1 | 0 | 0 |
| Disease Control Rate (CR+PR+SD) | 16 | 0 | 0 | 0 |
Treatment emergent adverse events (TEAEs) were defined as AEs that occurred on or after the first dose of study medication up to and including 30 days after last dose. AEs were graded according to NCI CTCAE (Version 4.0). Patients with multiple TEAEs were only counted once within a summary category: SOC, PT, maximum grade, or relationship to treatment. Patients with events in more than one category were counted once within each category.
| Participants | APR-246 (4.5g/6hr) + PLD | APR-246 (4.5g/3hr) + PLD | APR-246 (4.5g/4hr) + PLD | APR-246 (3.7g/4hr) + PLD |
|---|---|---|---|---|
| With Any Treatment-Emergent Adverse Events (TEAEs) | 28 | 3 | 2 | 3 |
| With APR-246 Related TEAEs | 25 | 3 | 2 | 3 |
| With PLD Related TEAEs | 24 | 3 | 2 | 3 |
| With Severity Grade >=3 | 14 | 3 | 2 | 3 |
| With Severity Grade >=3 APR-246 Related TEAEs | 6 | 2 | 2 | 2 |
| With Severity Grade >=3 PLD Related TEAEs | 7 | 2 | 0 | 2 |
| With Any Serious AEs | 11 | 1 | 1 | 2 |
| With Any Serious, APR-246 Related AEs | 4 | 1 | 1 | 1 |
| With Any Serious, PLD Related AEs | 2 | 1 | 0 | 1 |
| Who Discontinued APR-246 Due to TEAEs | 2 | 1 | 0 | 0 |
| Who Discontinued PLD Due to TEAEs | 0 | 0 | 0 | 0 |
| Who Died Due to any TEAEs | 0 | 0 | 0 | 0 |
Collected over Treatment emergent adverse events (TEAEs) were defined as AEs that occurred on or after the first dose of study medication up to and including 30 days after last dose. Median number of 28d Cycles=2.5 (Min = 1, Max = 14). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| APR-246 (4.5g/6hr) + PLD | 9/28 (32.1%) | 11/28 (39.3%) | 28/28 (100%) |
| APR-246 (4.5g/3hr) + PLD | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| APR-246 (4.5g/4hr) + PLD | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| APR-246 (3.7g/4hr) + PLD | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Event | APR-246 (4.5g/6hr) + PLD | APR-246 (4.5g/3hr) + PLD | APR-246 (4.5g/4hr) + PLD | APR-246 (3.7g/4hr) + PLD |
|---|---|---|---|---|
| DizzinessNervous system disorders | 0/28 | 0/3 | 1/2 | 0/3 |
| InfectionInfections and infestations | 0/28 | 1/3 | 0/2 | 1/3 |
| Device related infectionInfections and infestations | 0/28 | 0/3 | 0/2 | 1/3 |
| Respiratory tract infectionInfections and infestations | 0/28 | 0/3 | 0/2 | 1/3 |
| Urinary tract infectionInfections and infestations | 0/28 | 1/3 | 0/2 | 0/3 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/28 | 1/3 | 0/2 | 0/3 |
| Intestinal obstructionGastrointestinal disorders | 3/28 | 0/3 | 0/2 | 0/3 |
| NauseaGastrointestinal disorders | 1/28 | 0/3 | 0/2 | 0/3 |
| Peritoneal fibrosisGastrointestinal disorders | 1/28 | 0/3 | 0/2 | 0/3 |
| Small intestinal obstructionGastrointestinal disorders | 1/28 | 0/3 | 0/2 | 0/3 |
| Event | APR-246 (4.5g/6hr) + PLD | APR-246 (4.5g/3hr) + PLD | APR-246 (4.5g/4hr) + PLD | APR-246 (3.7g/4hr) + PLD |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 17/28 | 2/3 | 1/2 | 3/3 |
| VomitingGastrointestinal disorders | 12/28 | 2/3 | 2/2 | 3/3 |
| Abdominal painGastrointestinal disorders | 9/28 | 0/3 | 1/2 | 3/3 |
| FatigueGeneral disorders | 6/28 | 3/3 | 1/2 | 3/3 |
| DizzinessNervous system disorders | 5/28 | 1/3 | 2/2 | 1/3 |
| Decreased appetiteMetabolism and nutrition disorders | 7/28 | 1/3 | 1/2 | 3/3 |
| ConstipationGastrointestinal disorders | 11/28 | 1/3 | 0/2 | 2/3 |
| DiarrheaGastrointestinal disorders | 6/28 | 0/3 | 0/2 | 2/3 |
| Gastroesophageal reflux diseaseGastrointestinal disorders | 0/28 | 0/3 | 0/2 | 2/3 |
| Device occlusionGeneral disorders | 0/28 | 0/3 | 0/2 | 2/3 |
Patients with Pt-resistant HGSOC with TP53 mutation.
| Age, Categorical(Participants) | APR-246 (4.5g/6hr) + PLD | APR-246 (4.5g/3hr) + PLD | APR-246 (4.5g/4hr) + PLD | APR-246 (3.7g/4hr) + PLD | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 21 | 2 | 1 | 2 | 26 |
| >=65 years | 7 | 1 | 1 | 1 | 10 |
| Sex: Female, Male(Participants) | APR-246 (4.5g/6hr) + PLD | APR-246 (4.5g/3hr) + PLD | APR-246 (4.5g/4hr) + PLD | APR-246 (3.7g/4hr) + PLD | Total |
|---|---|---|---|---|---|
| Female | 28 | 3 | 2 | 3 | 36 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | APR-246 (4.5g/6hr) + PLD | APR-246 (4.5g/3hr) + PLD | APR-246 (4.5g/4hr) + PLD | APR-246 (3.7g/4hr) + PLD | Total |
|---|---|---|---|---|---|
| White | 27 | 3 | 2 | 3 | 35 |
| Asian | 1 | 0 | 0 | 0 | 1 |
| Region of Enrollment(participants) | APR-246 (4.5g/6hr) + PLD | APR-246 (4.5g/3hr) + PLD | APR-246 (4.5g/4hr) + PLD | APR-246 (3.7g/4hr) + PLD | Total |
|---|---|---|---|---|---|
| Belgium | 4 | 0 | 0 | 0 | 4 |
| United Kingdom | 3 | 3 | 2 | 3 | 11 |
| Spain | 21 | 0 | 0 | 0 | 21 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2017 to primary completion in Jul 2019, 23 months.
Results were first posted in Jul 2022, 3 years after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 23 months is below that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eprenetapopt
Aprea Therapeutics